Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Eloise Planchat"'
Autor:
Marie Viala, Jean-Baptiste Chadeyras, Béatrice Morio, Emilie Gadéa, Emilie Thivat, Eloise Planchat, Qian Wang-Lopez, Charles Merlin, Xavier Durando, Yves-Jean Bignon, Bruno Coudert, Rodolphe Paulon
Publikováno v:
Bulletin du Cancer. 100:865-870
Numerous studies have demonstrated that a significant change in weight during chemotherapy treatment was a factor of poor prognosis in early breast cancer women. However, the causes and mechanisms involved in this phenomenon are not fully known. This
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80f7d9421055606e9fcdf8410b7fd618
https://doi.org/10.1684/bdc.2013.1802
https://doi.org/10.1684/bdc.2013.1802
Autor:
Joseph Gligorov, Praagh-Doreau I Van, Nicole Tubiana-Mathieu, Christelle Jouannaud, M-A Mouret-Reynier, Frédérique Penault-Llorca, Laurence Vanlemmens, B. Nayl, Bettina Weber, F Mayer, H Devaud, Pascale Dubray-Longeras, J. P. Ferriere, Eloise Planchat, Thierry Petit, N. Chalabi, Fabrice Kwiatkowski, J-M Nabholtz, P. Chollet, Catherine Abrial, Olivier Tredan
Publikováno v:
Cancer Research. 71:P3-14
Background: Panitumumab is an antibody targeting the epidermal growth factor receptor (EGFR) to which a role has been suggested in TNBC. Consequently, we evaluated the combination of a standard chemotherapy (FEC 100 followed by T) with panitumumab as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f25b5d2b5ddf626dbcf079ef5e8e5800
https://doi.org/10.1158/0008-5472.sabcs11-p3-14-01
https://doi.org/10.1158/0008-5472.sabcs11-p3-14-01
Autor:
P. Chollet, Catherine Abrial, Eloise Planchat, Q. Wang-Lopez, Xavier Durando, Emilie Thivat, Jean-Marc Nabholtz, Marie-Ange Mouret-Reynier, Fabrice Kwiatkowski, C. Pomel
Publikováno v:
The Breast. 20:574-578
Metastatic breast cancer is mostly incurable. Progressively overall survival (OS) has improved but few authors have studied treatment globally versus for each line and demonstrated the interest of chemotherapy (CT) after the third line. We selected r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de831bc222243198687ce9af3ccba582
https://doi.org/10.1016/j.breast.2011.07.010
https://doi.org/10.1016/j.breast.2011.07.010
Autor:
Philippe Chollet, Françoise Gachon, Chantal Barthomeuf, Eloise Planchat, Marie-Ange Mouret-Reynier, Mathilde Bayet-Robert, Marianne Leheurteur, Xavier Durando, Fabrice Kwiatkowski, Catherine Abrial
Publikováno v:
Cancer Biology & Therapy. 9:8-14
Since the improvement of chemotherapy with safe molecules is needed for a better efficacy without supplementary toxicity, we investigated the feasibility and tolerability of the combination of docetaxel and curcumin, a polyphenolic derivative extract
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86a6f1cb88460f5f8d3afc464142b539
https://doi.org/10.4161/cbt.9.1.10392
https://doi.org/10.4161/cbt.9.1.10392
Autor:
Mathilde Bayet-Robert, Marc Atger, Hakim Mahammedi, Xavier Durando, Isabelle Van-Praagh, Laurent Guy, Jean-Christophe Eymard, Catherine Abrial, Laurent Savareux, Philippe Chollet, Hervé Curé, Mélanie Pouget, Emilie Thivat, Emilie Gadéa, Eloise Planchat
Publikováno v:
Oncology. 90(2)
Objectives: Favorable phase I results justified this pilot phase II study to assess the efficacy of docetaxel/curcumin in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (CRPC). Methods: Thirty patients with progressi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b08e48dc36a1a36e2821c3fdd4e04ac4
https://pubmed.ncbi.nlm.nih.gov/30613476
https://pubmed.ncbi.nlm.nih.gov/30613476
Autor:
Fabrice Kwiatkowski, Hakim Mahammedi, Pauline Herviou, Mélanie Pouget, Isabelle Van Praagh, Joyce Dohou, Eloise Planchat, Pascale Dubray-Longeras, Hervé Devaud, Catherine Abrial, Marie Arbre, Marie-Ange Mouret-Reynier, Philippe Chollet, Xavier Durando
Publikováno v:
Oncology. 89(6)
Background: Everolimus (Afinitor®) plus exemestane are indicated for hormone receptor-positive, HER2/neu-negative metastatic breast cancer (MBC), in menopausal women without symptomatic visceral disease after recurrence or progression following arom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89187340e2ff425222a0719eb82ae502
https://pubmed.ncbi.nlm.nih.gov/26457979
https://pubmed.ncbi.nlm.nih.gov/26457979
Autor:
Philippe Chollet, Catherine Abrial, Xavier Durando, Qian Wang-Lopez, Marie-Ange Mouret-Reynier, Fabrice Kwiatkowski, Pascale Dubray-Longeras, Frédérique Penault-Llorca, Pierre Gimbergues, Emilie Gadéa, Eloise Planchat, Hervé Curé
Publikováno v:
The Breast Journal. 19:448-450
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e91befc4158561eeccb07852be26694
https://doi.org/10.1111/tbj.12131
https://doi.org/10.1111/tbj.12131
Autor:
Philippe Chollet, Catherine Abrial, C. Pomel, Emilie Thivat, Marie-Ange Mouret-Reynier, Jean-Marc Nabholtz, Fabrice Kwiatkowski, Jean-Pierre Ferriere, Eloise Planchat, Xavier Durando
Publikováno v:
Cancer investigation. 29(9)
Classical prognostic factors of breast cancer are correlated to disease-free survival and overall survival (OS); their precise role is less known on metastatic disease. A total of 511 breast cancer patients without initial metastasis were treated. OS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::898f1a1acfbf448ee10962b905137482
https://pubmed.ncbi.nlm.nih.gov/22506656
https://pubmed.ncbi.nlm.nih.gov/22506656
Autor:
Catherine Abrial, Emilie Thivat, Emilie Gadéa, Eloise Planchat, Zuzana Tatar, Pierre Gimbergues, Xavier Durando
Publikováno v:
Cancer treatment reviews. 39(2)
Temozolomide (TMZ) was first known to be useful as a radiosensitiser in both primary brain tumours like glioblastoma multiforme and oligodendroglioma. Later, TMZ proved its efficacy in the treatment of melanoma. Multiple publications have demonstrate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c96759077d187d890fe24133d3953fd8
https://pubmed.ncbi.nlm.nih.gov/22818211
https://pubmed.ncbi.nlm.nih.gov/22818211
Autor:
Emilie Gadéa, Philippe Chollet, Olivier Lapirot, Eloise Planchat, Marie A Mouret-Reynier, Fabrice Kwiatkowski, Xavier Durando, P. Gimbergues, Catherine Abrial, Sophie Thérondel, Emilie Thivat
Publikováno v:
BMC Cancer
BMC Cancer, BioMed Central, 2010, 10 (1), pp.648. ⟨10.1186/1471-2407-10-648⟩
BMC Cancer, Vol 10, Iss 1, p 648 (2010)
BMC Cancer, BioMed Central, 2010, 10 (1), pp.648. ⟨10.1186/1471-2407-10-648⟩
BMC Cancer, Vol 10, Iss 1, p 648 (2010)
Background Weight change during chemotherapy is reported to be associated with a worse prognosis in breast cancer patients, both with weight gain and weight loss. However, most studies were conducted prior to the common use of anthracycline-base chem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be806e15f857d6365759a9153acc6356
https://www.hal.inserm.fr/inserm-00663871/document
https://www.hal.inserm.fr/inserm-00663871/document
